Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth [Yahoo! Finance]
Monte Rosa Therapeutics, Inc. (GLUE)
Company Research
Source: Yahoo! Finance
lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse. Given this risk, we thought we'd take a look at whether Monte Rosa Therapeutics NASDAQ:GLUE ) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. First, we'll determine its cash runway by comparing its cash burn with its cash reserves. Check out our latest analysis for Monte Rosa Therapeutics When Might Monte Rosa Therapeutics Run Out Of Money? You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. In June 2024, Monte Rosa Therapeutics had US$262m in cash, and was debt-free. Look
Show less
Read more
Impact Snapshot
Event Time:
GLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLUE alerts
High impacting Monte Rosa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GLUE
News
- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.MarketBeat
- Monte Rosa Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 StudyGlobeNewswire
- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) had its price target lowered by analysts at Wells Fargo & Company from $18.00 to $17.00. They now have an "overweight" rating on the stock.MarketBeat
- Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
GLUE
Earnings
- 8/8/24 - Beat
GLUE
Sec Filings
- 9/24/24 - Form SC
- 9/24/24 - Form 4
- 9/13/24 - Form 4
- GLUE's page on the SEC website